+1 Recommend
1 collections
      Call for Papers in Kidney and Blood Pressure ResearchKidney Function and Omics Science

      Submission Deadline: December 20, 2023

      Submit now

      • Record: found
      • Abstract: found
      • Article: found

      Recent Insights into Experimental Mouse Models of Diabetic Nephropathy


      Read this article at

          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.


          Background/Aims: Mouse models are an essential experimental tool for investigating the role of molecular mechanisms and genetic susceptibility in the development of diabetic nephropathy. Methods: The most widely used inbred strain, the C57BL/6 mouse, is commonly used in streptozotocin-induced models of type 1 diabetes and is particularly susceptible to obesity-induced type 2 diabetes. However, use of this strain has been criticised by studies suggesting that it is relatively resistant to renal injury. Results: Recent refinement of these models and utilisation of genetically modified (knockout and transgenic) mice on a C57BL/6 background has provided important insights into the roles of oxidative stress, advanced glycation end products, inflammation and profibrotic mechanisms in the development of type 1 and type 2 diabetic nephropathy. Conclusion: These findings demonstrate the utility of mouse models for identifying and testing novel therapeutic strategies which could translate into better protection against the human disease.

          Related collections

          Author and article information

          Nephron Exp Nephrol
          Cardiorenal Medicine
          S. Karger AG
          September 2006
          21 June 2006
          : 104
          : 2
          : e57-e62
          aDepartment of Nephrology and bMonash University Department of Medicine, Monash Medical Centre, Clayton, Australia
          93998 Nephron Exp Nephrol 2006;104:e57–e62
          © 2006 S. Karger AG, Basel

          Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher. Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug. Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.

          : 16 January 2006
          : 20 March 2006
          Page count
          References: 34, Pages: 1
          Self URI (application/pdf): https://www.karger.com/Article/Pdf/93998
          Self URI (text/html): https://www.karger.com/Article/FullText/93998
          Self URI (journal page): https://www.karger.com/SubjectArea/Nephrology

          Cardiovascular Medicine,Nephrology
          Diabetic nephropathy,Oxidative stress,Advanced glycation end products,db/db,Streptozotocin,C57BL/6,Mouse models,Fibrosis


          Comment on this article